Entera Bio (ENTX) FCF Margin (2021 - 2025)

Entera Bio has disclosed FCF Margin across 4 years of filings, most recently posting 3361.9% for Q1 2025.

• Quarterly FCF Margin changed N/A year-over-year to 3361.9% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 17802.38% (down 1403387.0% YoY) and the FY2025 annual result came in at 17802.38%, down 1403387.0% from the prior year.
• FCF Margin fell to 3361.9% in Q1 2025, from 1792.68% in the prior quarter.
• Over five years, FCF Margin peaked at 1478.34% in Q1 2021 and troughed at 35887.5% in Q3 2022.
• A 4-year average of 6909.31% and a median of 2852.01% in 2024 frame the typical range for FCF Margin.
• Biggest YoY gain for FCF Margin was 452231 bps in 2022; the steepest drop was 3437607 bps in 2022.
• Tracing ENTX's FCF Margin over 4 years: stood at 1528.48% in 2021, then slumped by 841 bps to 14385.71% in 2022, then jumped by 88 bps to 1792.68% in 2024, then plunged by 88 bps to 3361.9% in 2025.
• Business Quant data shows ENTX's FCF Margin at 3361.9% in Q1 2025, 1792.68% in Q4 2024, and 5128.57% in Q3 2024.